Hospital HM Universitario Sanchinarro Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2012
NCT02261714
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Centro Integral Oncologico Clara Campal / Hospital HM Universitario Sanchinarro / Madrid | CIOCC (Hospital Universitario HM Sanchinarro)

Active Ingredients

Drugs in Phase 2 Trials (2)

apricoxib (1 trial)

enzalutamide (xtandi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2